CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo

/PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), today announced the presentation of preclinical data suggesting that the Company's chemogenetic gene...

Related Keywords

United States ,Chicago ,Illinois ,Americans ,American ,Quynh Anh Nguyen ,Peterm Klein ,Michael Narachi ,Ivan Soltesz ,Jesslyn Homidan ,Jamesr Doty ,Centers For Disease ,American Epilepsy Society ,Epilepsy Foundation ,World Health Organization ,Stanford University School Of Medicine ,Journal Of Pain Research ,Biotherapeutics Inc ,National Institute Of Neurological Disorders ,Stanford University School ,Focal Epilepsy ,Neuropathic Pain ,Disease Control ,National Institute ,Neurological Disorders ,Pain Research ,Coda Biotherapeutics ,Nc ,